Descriptive sample characteristics
| N | Minimum | Maximum | Mean | SD | 95% CI of mean | |
|---|---|---|---|---|---|---|
| Age | 236 | 21 | 84 | 56.87 | 13.39 | (55.16 to 58.59) |
| Duration of disease (years) | 236 | 0 | 44 | 9.11 | 8.88 | (7.97 to 10.24) |
| Sex (N female/N male) | 236 | 174 (73.7%)/62 (26.3%) | ||||
| Rheumatoid factor (N positive/N negative) | 234 | 180 (76.9%)/54 (23.1%) | ||||
| Cyclic citrullinated peptides antibodies (N positive/N negative) | 236 | 152 (64.4%)/84 (35.6%) | ||||
| Methotrexate therapy | 110 | |||||
| Glucocorticoid therapy | 93 | |||||
| Biological therapy | 131 | |||||
| Change of medication at visit (N yes/N no) | 234 | 60 (25.6%)/174 (74.4%) | ||||
| HAQ-DI (before consultation) | 231 | 0 | 2.88 | 0.89 | 0.75 | (0.79 to 0.98) |
| HAQ-DI (after consultation) | 230 | 0 | 3.00 | 0.88 | 0.76 | (0.78 to 0.98) |
| HAQ-DI (follow-up, total sample) | 208 | 0 | 3.00 | 0.85 | 0.76 | (0.74 to 0.95) |
| HAQ-DI (follow-up, days 6–13) | 111 | 0 | 2.63 | 0.69 | 0.69 | (0.56 to 0.82) |
| DAS28 (composite index) | 208 | 0 | 7.61 | 3.33 | 1.54 | (3.12 to 3.54) |
| VAS pain (before consultation) | 213 | 0 | 10.0 | 3.44 | 2.61 | (3.08 to 3.79) |
| VAS pain (after consultation) | 209 | 0 | 9.9 | 3.27 | 2.63 | (2.91 to 3.63) |
| VAS pain (follow-up, total sample) | 192 | 0 | 9.1 | 2.98 | 2.37 | (2.64 to 3.32) |
| VAS pain (follow-up, days 6–13) | 104 | 0 | 9.0 | 2.55 | 2.17 | (2.13 to 2.97) |
| NRS pain (before consultation) | 226 | 0 | 10 | 3.35 | 2.49 | (3.03 to 3.68) |
| NRS pain (after consultation) | 228 | 0 | 9 | 3.32 | 2.48 | (2.99 to 3.64) |
| NRS pain (follow-up, total sample) | 206 | 0 | 9 | 3.24 | 2.38 | (2.91 to 3.57) |
| NRS pain (follow-up, days 6–13) | 110 | 0 | 9 | 2.84 | 2.27 | (2.41 to 3.27) |
| VRS pain (before consultation) | 223 | 0 | 3 | 1.50 | 0.91 | (1.38 to 1.62) |
| VRS pain (after consultation) | 224 | 0 | 3 | 1.45 | 0.91 | (1.33 to 1.57) |
| VRS pain (follow-up, total sample) | 203 | 0 | 4 | 1.38 | 0.90 | (1.25 to 1.50) |
| VRS pain (follow-up, days 6–13) | 107 | 0 | 3 | 1.20 | 0.86 | (1.03 to 1.36) |
Annotation: table 1 shows descriptive information about the characteristics of the patient sample, including number of patients with data available (N), minimum and maximum values, arithmetic mean (mean), SD and 95% CI of the arithmetic mean (95% CI of mean). For categorical variables, the size of the corresponding subgroups is presented.
DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire-Disability Index; NRS, numerical rating scale; VAS, visual analogue scale; VRS, verbal rating scale.